LakeShore Biopharma Holds Shareholder Meeting

TL;DR

LAKESHORE BIOPHARMA (LSPB) had an extraordinary shareholder meeting in Sept 2024, details filed today.

AI Summary

LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) filed a 6-K report on September 27, 2024. The filing pertains to the results of an extraordinary general meeting of shareholders held in September 2024. The company is incorporated in China and its principal executive offices are located in Beijing.

Why It Matters

This filing indicates corporate governance activities and shareholder engagement, which can be important for investors assessing company direction and stability.

Risk Assessment

Risk Level: low — The filing is a routine report of a shareholder meeting and does not contain significant financial or operational news.

Key Players & Entities

• LakeShore Biopharma Co., Ltd. (company) — Registrant
• YS Biopharma Co., Ltd. (company) — Former company name
• YishengBio Co., Ltd (company) — Former company name
• September 2024 (date) — Period of report and month of shareholder meeting
• September 27, 2024 (date) — Filing date

FAQ

Key Financial Figures

• $0.00002 — e every 10 (ten) shares, par value of US$0.00002 each (whether issued or unissued), into
• $0.0002 — 1 (one) ordinary share, par value of US$0.0002 each (the “ Share Consolidation &
• $50,000 — f the Company shall be changed FROM US$50,000 divided into 2,500,000,000 ordinary sha

Filing Documents

• ea0215893-6k_lakeshore.htm (6-K) — 16KB
• ea021589301ex3-1_lakeshore.htm (EX-3.1) — 282KB
• ea021589301ex99-1_lakeshore.htm (EX-99.1) — 12KB
• 0001213900-24-082408.txt ( ) — 312KB

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission file number: 001-41598 LAKESHORE BIOPHARMA CO., LTD (Exact name of registrant as specified in its charter) Building No. 2, 38 Yongda Road Daxing Biomedical Industry Park Daxing District, Beijing, PRC Tel: 010-89202086 (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F RESULTS OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS The extraordinary general meeting of shareholders (the “ EGM ”) of LakeShore Biopharma Co., Ltd (the “ Company ”) was held at 10:00 a.m., on September 27, 2024 (Beijing time), virtually via a Zoom video conference call. At the EGM, the Company’s shareholders approved and adopted the following resolutions: 1. As an ordinary resolution, with effect from October 1, 2024, to consolidate every 10 (ten) shares, par value of US$0.00002 each (whether issued or unissued), into 1 (one) ordinary share, par value of US$0.0002 each (the “ Share Consolidation ”), such that following the Share Consolidation, the authorized share capital of the Company shall be changed FROM US$50,000 divided into 2,500,000,000 ordinary shares of a par value of US$0.00002 each TO US$50,000 divided into 250,000,000 ordinary shares of a par value of US$0.0002 each, and no fraction of a share shall be issued by virtue of the Share Consolidation, and all fractions of shares resulting from the Share Consolidation will be rounded up to the nearest whole number of shares and each shareholder that would otherwise be so entitled to a fraction of a share shall instead, as a result of the Share Consolidation, be entitled to receive a whole share. 2. As a special resolution, that with effect immediately following the Share Consolidation, the currently effective memorandum and articles of association of the Company be amended and restated by their deletion in their entirety and the substitution in their place of the second amended and restated memorandum and articles of association of the Company, in the form furnished herewith as Exhibit 3.1. The Company also issued a press release dated September 27, 2024, announcing the results of the EGM, which is furnished herewith as Exhibit 99.1. INCORPORATION BY REFERENCE This current report on Form 6-K, including Exhibit 3.1 and Exhibit 99.1 hereto, shall be deemed to be incorporated by reference into the Company’s registration statements on Form S-8 (File No. 333-279544 and File No. 333-273165 ) and to be a part thereof from the date on which this current report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished. 1 EXHIBITS Exhibit No. Description 3.1 The Second Amended and Restated Memorandum and Articles of Association of the Company 99.1 Press Release – LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation 2 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LakeShore Biopharma Co., Ltd By: /s/ Rachel Yu Name: Rachel Yu Title: Director and Chief Financial Officer Date: September 27, 2024 3

View Full Filing

View this 6-K filing on SEC EDGAR